DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

Becker's Hospital Review - Cardiology

JANUARY 13, 2025

"CMS proposes Medicare and Medicaid coverage for implantable pulmonary artery pressure sensors to manage heart failure. Final decision to be published on Jan.

CMS 52

CMS Heart Failure Medicaid Medicare 52

DAIC

JULY 25, 2024

FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heart failure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

DAIC

MARCH 7, 2024

Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. These patients saw more than a 17% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (2.9%

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105

DAIC

DECEMBER 8, 2023

The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy. I am excited to be able to include the advanced heart failure patients in the trial," commented Dr. Grafton.

Technology 113

Technology Heart Failure Heart Transplant Transplant 113

DAIC

MAY 2, 2024

About the CardiAMP Cell Therapy Program Designated by the FDA as a Breakthrough Therapy for Ischemic Heart Failure, CardiAMP Cell Therapy uses a patient’s own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response.

Ischemia 95

Ischemia Angina Heart Failure Outcomes 95

American College of Cardiology

FEBRUARY 1, 2025

Initiatives such as the World Health Organization's "Medication Without Harm" and the Centers for Medicare and Medicaid Services' (CMS) expanded quality measures aim to reduce preventable emergency visits and hospital admissions due to medication-related harm. BMC Med2015;13(74). Page RL 2nd, O'Bryant CL, Cheng D, et al. Circulation.

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease CMS Hospital 40